Free tool
FAERS Monitor: Fioricet W/ Codeine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020232 or its brand name (Fioricet W/ Codeine, Acetaminophen, Butalbital, Caffeine, Codeine Phosphate). Reports on generic versions are filed under their own applications.
Reports
38
Serious
35
92% of reports
Hospitalization
1
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dependence27
- overdose15
- completed suicide5
- death3
- drug ineffective3
- cardio-respiratory arrest2
- maternal exposure during pregnancy2
- withdrawal syndrome2
- aggression1
- anxiety1
- blood testosterone decreased1
- constipation1
- depression1
- drug abuse1
- drug dependence1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 27 |
| 2024 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,121 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dependenceSignal | 27 | 272.7 | 222.6 | 7,056 |
| blood testosterone decreased | 1 | 80.9 | 11.7 | 19 |
| overdoseSignal | 15 | 38.5 | 26.0 | 516 |
| completed suicideSignal | 5 | 33.2 | 14.7 | 126 |
| cardio-respiratory arrest | 2 | 26.5 | 6.9 | 27 |
| withdrawal syndrome | 2 | 26.4 | 6.8 | 27 |
| maternal exposure during pregnancy | 2 | 12.4 | 3.2 | 11 |
| aggression | 1 | 11.1 | 1.6 | 2 |
| drug abuse | 1 | 6.6 | 1.0 | 1 |
| drug dependence | 1 | 3.4 | 0.5 | 0 |
| constipation | 1 | 2.5 | 0.4 | 0 |
| depression | 1 | 2.4 | 0.4 | 0 |
| anxiety | 1 | 1.9 | 0.3 | 0 |
| death | 3 | 1.9 | 0.7 | 1 |
| drug ineffective | 3 | 1.3 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.